Ibrunat contains Ibrutinib 140mg, a targeted cancer therapy used to treat certain blood cancers such as Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM).
| Composition | Ibrutinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Capsules |
| Prescribed For | Blood Cancers |
| Expiry | December 2027 |
Nitib contains Ibrutinib 140mg, a targeted therapy used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia.
| Composition | Ibrutinib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 30 Capsules |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
